Hari Vigneswaran, MD

Urologist | @Karolinskainst

[Adam B. Weiner, MD @Adam_Weiner535]

🚨#ProstaCancer early detection🚨

Lots to look forward to in future trials and implementing modern appproahces to screening

#EAU26

[Daniel E Spratt @DrSpratticus]

Ppl understandably bring up concerns on a population level with expanding screening in men >70yo.

Let us dive into data on this. I agree with @VickersBiostats we should always do 'risk stratified' screening whether >70 or <70yo (we should not be doing PSA screening in a 50 yo with a terminal condition with <1yr to live).

@ASTRO_org @ASCO @PCF_Science

[Daniel E Spratt @DrSpratticus]

X-torial: Cleaning up the misinformation about @JoeBiden and #ProstateCancer that I am reading everywhere.

The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA @NCCN PCa guidelines, hold leadership in @NRGonc @theNCI @US_FDA and dedicated my career to help men and their families suffering from PCa

@nytimes @WSJ @FoxNews @CNN @NBCNews @Reuters @ASCO @PCFnews @DeptofDefense

[Keith Kowalczyk, MD @KeithKow]

This. We see this every day. It’s how GG5 presents. Anyone saying otherwise does not treat prostate cancer.

[Hari Vigneswaran, MD @HVigneswaran]

Accurate, eloquent, and refreshingly candid by @daviesbj

[Benjamin J. Davies MD, MBA @daviesbj]

On NPR this morning with @NPRinskeep

Tried to give a broader view of metastatic prostate cancer landscape.

https://t.co/JEUfc2XHKV

[Benjamin J. Davies MD, MBA @daviesbj]

On NPR this morning with @NPRinskeep

Tried to give a broader view of metastatic prostate cancer landscape.

https://t.co/JEUfc2XHKV

[Matt Cooperberg @dr_coops]

More progress on the #stockholm3 screening/confirmatory test for #prostatecancer. This one is definitely a test to watch @Tilki_De #aua25

[Matt Cooperberg @dr_coops]

Valiant effort @UFalagario to revisit the question of BCR definition comparability for RP vs. RT for #prostatecancer. Closest seems to be nadir + 0.5 for RT vs. &gt;0.5 with PSADT &lt;9mos for RP.

I still personally want CSM outcomes for CER studies, but this is very helpful. #AUA25

[Matt Cooperberg @dr_coops]

Finally a marker study using PSA &gt;1 as the threshold to move on to secondary testing for #prostatecancer.

#thisistheway 🙌 Great #stockholm3 study #aua25.

[Adam B. Weiner, MD @Adam_Weiner535]

🚨TP vs TR prostate biopsy🚨

📜TRANSLATE RCT out in @TheLancetOncol

👉Transperineal biopsy...
1⃣More ≥GG2 #prostatecancer detected
2⃣Similar to possibly fewer infections WITHOUT any antibiotic prophylaxis

🔗https://t.co/hL1a0qUcfo

👏#EAU25 @LabBryant @LambAlastair @PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @ZEROCancer

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Correlates between PSMA PET and MRI for clinically significant #ProstateCancer 🚨

Our group just published in @JournalofNucMed

👉 132 tumors GG>2 from 100 pts who got both PET and MRI prior to prostatectomy @UCLAHealth

🗣️📢PET detects more tumors compared to MRI by:
1⃣Lesion (87% v 80%) &
2⃣Patient (98% v 94%)

3⃣GG2+ Tumors detected by PET but not by MRI tended to be smaller on pathology

👏Ida Sonni, MD

@RobertReiterMD @StevenSRaman_MD @CalaisJeremie @uclawillhsu @CzerninJohannes @UclaUrology @PCFnews @PCF_Science @AmerUrological @SUO_YUO @UroOnc

[Urology Times @UrologyTimes]

Stockholm3 demonstrated the ability to reduce unnecessary biopsies compared with PSA across a multiethnic cohort of patients, according to data from the SEPTA trial. @HVigneswaran #pcsm #urology
https://t.co/IJq0xhu1iY

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Stockholm3 in a multiethnic cohort🚨

📄@JCO_ASCO

Compared with PSA, Stockholm3 test can 📉 unnecessary biopsies

Finally, great data on a #prostatecancer biomarker from a diverse cohort (n~2k):

Asian: 16%
Black : 24 %
Hispanic: 14%

👏 @HVigneswaran @DrAdamMurphy

@PCF_Science @PCFnews @UrologyTimes @urotoday

🔗 https://t.co/Dl7DRk7Yn1

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA) out on @JCO_ASCO

https://t.co/aIRD8uh4YH

The study aimed to assess the effectiveness of the Stockholm3 🇸🇪test in improving prostate cancer detection in a diverse cohort, including Asian, Black, Hispanic, and White men, who are typically underrepresented in clinical trials

Conducted as an observational, prospective multicenter trial, it included 2,129 participants with suspected #ProstateCancer .

➡️The primary objectives were to evaluate the noninferior sensitivity of Stockholm3 compared to prostate-specific antigen (PSA) levels and to demonstrate superior specificity in reducing unnecessary biopsies.
➡️The findings showed that Stockholm3 had comparable sensitivity to PSA in detecting clinically significant prostate cancer and significantly higher specificity, reducing benign and low-grade cancer biopsies by 45% overall.

The test performed consistently across all racial and ethnic groups, suggesting it as an effective tool for improving prostate cancer detection and reducing unnecessary procedures.

@HVigneswaran
@TobiasNordstrom
@RhubbBstat
@Nptdot
@michaelabern
@uroegg
@KaraWattsMD
@lissmike
@ALDCAbreu
@geoffsonn
@TPalsdotti
Henrik Grönberg, @karolinskainst
Adam B. Murphy

[Scott Eggener @uroegg]

History repeats itself.......

Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial - European Urology https://t.co/ZcQL0TVJiY

[Thorgerdur Palsdottir @TPalsdotti]

Showing the great results from using Stockholm3 test with MRI to diagnose prostate cancer in a more effective way #stockholm3 #urology #prostatecancerdiagnosis
@HVigneswaran @henrikgronberg1
https://t.co/TaHNEXmPPt

[Scott Eggener @uroegg]

North American validation of STHLM3 in a large diverse cohort undergoing prostate biopsy; able to maintain relative sensitivity for GG2 and higher with far superior specificity (compared to PSA)

[UroToday.com @urotoday]

#Stockholm3 validation in a multi-ethnic cohort for #ProstateCancer (SEPTA) detection: a multicentered, prospective trial. Presentation by @uroegg @UChicago. #GU24 written coverage by @RKSayyid @UofT &gt; https://t.co/qG5pjYJVaS @ASCO

[Hari Vigneswaran, MD @HVigneswaran]

Great to see the Stockholm3 SEPTA trial presented at #GU24! A racially diverse validation and a huge team effort

https://t.co/QcdMdq6hUX

@TobiasNordstrom @Nptdot @michaelabern @uroegg @KaraWattsMD @alexanderchowmd @TPalsdotti @lissmike @ALDCAbreu @geoffsonn @DrAdamMurphy

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#262 @ASCO #GU24 #HariT.👉https://t.co/sveelRIODT👉Stockholm 3 blood test vs PSA testing in SEPTA trial for #prostatecancer 👉 superior specificity vs PSA test ➡️avoid unnecessary bx👇@DrAdamMurphy @OncoAlert @urotoday @PCF_Science @Uromigos